Fairvalue-Calculator Fairvalue-Calculator
EN DE

Formosa Pharmaceuticals, Inc (6838) Fair Value & Analysis

Healthcare · TW · Market cap 3.7B TWD

Price23.85 TWD
Fair Value28.94 TWD
Upside+21.3%
Quality95/100
Evidence: Low Range 21.71 TWD – 36.18 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Formosa Pharmaceuticals, Inc (6838) currently trades at 23.85 TWD, while our model-based Fair Value estimate is 28.94 TWD — implying the stock looks roughly 21.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic; and Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Formosa Pharmaceuticals, Inc (6838) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 28.94 TWD versus a price of 23.85 TWD — about +21% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6838?
Our 21-model fair value for Formosa Pharmaceuticals, Inc is 28.94 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 23.85 TWD.
What is the quality score of 6838?
Formosa Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.